American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 455-466 , November 2008

Black cohosh (Cimicifuga racemosa): a systematic review of adverse events

  • Francesca Borrelli, PhD

      Affiliations

    • Department of Experimental Pharmacology, University of Naples Federico II, Naples, Italy
    • Corresponding Author InformationReprints: Francesca Borrelli, PhD, Department of Experimental Pharmacology, University of Naples Federico II, Via D Montesano 49, 80131 Naples, Italy
    • ,
  • Edzard Ernst, MD, PhD

      Affiliations

    • Department of Complementary Medicine, Peninsula Medical School, Universities of Exeter & Plymouth, Exeter UK

Received 23 January 2008 ,Accepted 19 May 2008.

References 

  1. Eisenberg D, David RB, Ettner SL, et al. Trends in alternative medicine use in the United States; 1990-1997. JAMA. 1998;280:1569–1575
  2. Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med. 2005;11:42–49
  3. Ernst E. Prevalence of use of complementary/alternative medicine: a systematic review. Bull World Health Organ. 2000;78:252–257
  4. Xue CC, Zhang AL, Lin V, Da Costa C, Story DF. Complementary and alternative medicine use in Australia: a national population-based survey. J Altern Complement Med. 2007;13:643–650
  5. Fukuda S, Watanabe E, Ono N, Tsubouchi M, Shirakawa T. Use of complementary and alternative medicine and health problems. Nippon Koshu Eisei Zasshi. 2006;53:293–300
  6. Nicholson T. Complementary and alternative medicines (including traditional Maori treatments) used by presenters to an emergency department in New Zealand: a survey of prevalence and toxicity. N Z Med J. 2006;119:U1954
  7. National Center for Complementary and Alternative Medicine. http:nccam.nih.gov/health/whatiscam/Accessed January 10, 2008
  8. Kam IW, Dennehy CE, Tsourounis C. Dietary supplement use among menopausal women attending a San Francisco health conference. Menopause. 2002;9:72–78
  9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613
  10. Rossouw JE, Anderson GL, Prentice RL, et al. writing group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  11. MacLennan AH, Taylor AW, Wilson DH. Hormone therapy use after the Women's Health Initiative. Climacteric. 2004;7:138–142
  12. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004;140:184–188
  13. Foster S. Black cohosh: Cimicifuga racemosa: a literature review. Herbal Gram. 1999;45:35–50
  14. Nuntanakorn P, Jiang B, Einbond LS, et al. Polyphenolic constituents of Actaea racemosa. J Nat Prod. 2006;69:314–318
  15. Fabricant DS, Nikolic D, Lankin DC, et al. Cimipronidine, a cyclic guanidine alkaloid from Cimicifuga racemosa. J Nat Prod. 2005;68:1266–1270
  16. Burdette JE, Liu J, Chen SN, et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem. 2003;51:5661–5670
  17. American College of Obstetricians and Gynecologists. Use of botanicals for management of menopausal symptoms: ACOG Practice Bulletin. Obstet Gynecol. 2001;28:1–11
  18. Huntley A, Ernst E. A systematic review of the safety of black cohosh. Menopause. 2003;10:58–64
  19. Dog TL, Powell KL, Weisman SM. Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief. Menopause. 2003;10:299–313
  20. Kesselkaul O. Uber die Behandlung klimakterischer Beschwerden mit Remifemin. Med Monatsschr. 1957;11:87–88
  21. Schotten EW. Erfahrungen mit dem Cimicifuga-Praparat Remifemin. Landarzt. 1958;34:353–354
  22. Stefan H. Ein Beitrag zu den erscheinungsformen und zur therapie hormonal bedingter biopathiesyndrome der Frau. Ringelheimer Biol Umsch. 1959;14:149–152
  23. Foldes J. The actions of an extract of Cimicifuga racemosa. Arzneimittelforschung. 1959;13:623–624
  24. Stiehler K. Uber die Anwendung eines standardisierten Cimicifuga-Auszuges in der Gynakologie. Arztliche Praxis. 1959;11:916–917
  25. Heizer H. Kritisches zur Cimicifuga: therapie bei hormonalen storungen der Frau. Med Klin. 1960;55:232–233
  26. Brucker A. Beitrag zur phytotherapie hormonaler storungen der frau. Med Welt. 1960;44:2331–2333
  27. Starfinger W. Therapie mit oestrogen wirksamen Pfanzenextrakten. Med Heute. 1960;9:173–174
  28. Gorlich N. Behandlung ovarieller storungen der frau in der allgemein-praxis. Arztliche Praxis. 1962;14:1742–1743
  29. Langfritz W. Beitrag zur Therapie von Regelanomalien und deren Begleiterscheinungen bei jungen Madchen und jungen Frauen. Med Klin. 1962;57:1497–1499
  30. Schildge E. Beitrag zur Behandlung von pramenstruellen und klimakterischen Vestimmungs und Depression-Zustanden. Ringelh Biol Umsch. 1964;19:18–22
  31. Stolze H. An alternative to treat menopausal complaints. Gyne. 1982;3:14–16
  32. Daiber W. Climacteric complaints: success without using hormones: a phytotherapeutic agent lessens hot flushes, sweating and insomnia. Arztliche Praxis. 1983;35:1946–1947
  33. Vorberg G. Therapy of climateric complaints. Zeitschrift fur Allgemeinmedizin. 1984;60:626–629
  34. Warnecke G. Influence of a phytopharmaceutical on climacteric complaints. Die Meizinisch Welt. 1985;36:871–874
  35. Stoll W. Phytopharmacon influences atrophic vaginal epithelium: double-blind study: cimicifuga vs estrogenic substances. Therapeuticum. 1987;1:23–31
  36. Petho A. Climacteric complaints are often helped with black cohosh. Arztliche Praxis. 1987;47:1551–1553
  37. Lehmann WE, Riedel HH. Clinical and endocrinologic examinations about therapy of climateric symptoms following hysterectomy with remaining ovaries. Zentralbl Gynakol. 1988;110:611–618
  38. Duker EM, Kopanski L, Jarry H, Wuttke W. Effects of extracts from Cimicifuga racemosa on gonadotropin release in menopausal women and ovariectomised rats. Planta Med. 1991;57:420–424
  39. Balier-Jagodzinski G. Praxisstudien mit Cimisan bei klimaterischen Beschwerden, Pramenstruellem Syndrom und Dysmenorrhoe. Natur Heilpraxis Naturmedizin. 1995;48:1284–1288
  40. Georgiev DB, Iordanova E. Phytoestrogens: the alternative approach. Maturitas. 1997;27:213
  41. Mielnik J. Extract of Cimicifuga racemosa in the treatment of neurovegetative symptoms in women in the perimenipausal period. Maturitas. 1997;27:215
  42. Liske E, Wustenberg P. Therapy of climacteric complaints with Cimicifuga racemosa: herbal medicine with clinically proven evidence. Menopause. 1998;5:250
  43. Nesselhut T, Liske E. Pharmacological measures in postmenopausal women with an isopropanolic aqueous extract of Cimicifuga racemosae rhizome. Menopause. 1999;6:1072–3714
  44. Boblitz N, Schrader E, Henneicke-von Zepelin HH, Wustenberg P. Benefit of a a fixed drug combination containing St. John's wort and black cohosh for climateric patients: results of a randomized clinical trial. (poster presentation from: 6th Annual Symposium on Complemetary Health Care; Exeter, England; December 2-4, 1999) Focus alt Comp Ther (Fact). 2000;5:85–86
  45. Jacobson JS, Troxel AB, Evans J, et al. Randomised trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. 2001;19:2739–2745
  46. Look RM, Morris KT, Homer L, et al. Randomized controlled trial of venlafaxine versus black cohosh as a treatment for menopausal symptoms in women with breast cancer [abstract]. Proc Am Soc Clin Oncol. 2001;20:305b;abstract 2973
  47. Cook A, Pennington G. Phytoestrogen and multiple vitamin/mineral effects on bone mineral density in early postmenopausal women: a pilot study. J Womens Health Gend Based Med. 2002;11:53–60
  48. Burke BE, Olson RD, Cusack BJ. Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed Pharmacother. 2002;56:283–288
  49. Liske E, Hanggi W, Henneicke-von Zepelin HH, Boblitz N, Wustenberg P, Rahlfs VW. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systematic estrogenic effect. J Womens Health Gend Based Med. 2002;11:163–174
  50. Wuttke W, Seidlová-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas. 2003;44:67–77
  51. Hernandez Munoz G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas. 2003;44:59–65
  52. Morris K, Look RM, Hudson V, et al. The efficacy and safety of black cohosh for managing menopausal symptoms in breast cancer survivors [abstract]. Breast Cancer Res Treat. 2003;82(suppl):S159
  53. Johnson BM, van Breemen RB. In vitro formation of quinoid metabolites of the dietary supplement Cimicifuga racemosa (black cohosh). Chem Res Toxicol. 2003;16:838–846
  54. Pockaj BA, Loprinzi CL, Sloan JA, et al. Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest. 2004;22:515–521
  55. Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin HH. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol. 2005;105:1074–1083
  56. Frei-Kleiner S, Schaffner W, Rahlfs VW, Bodmer C, Birkhauser M. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas. 2005;51:397–404
  57. Nappi RE, Malavasi B, Brundu B, Facchinetti F. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol. 2005;20:30–35
  58. Newton KM, Reed SD, Grothaus L, et al. The Herbal Alternatives for Menopause (HALT) study: background and study design. Maturitas. 2005;52:134–146
  59. Verhoeven MO, van der Mooren MJ, van de Weijer PH, et al. CuraTrial Research Group Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause. 2005;12:412–420
  60. Smolinski D, Wollner D, Orlowski J, Curcio J, Nevels J, Kim LS. A pilot study to examine a combination botanical for the treatment of menopausal symptoms. J Altern Complement Med. 2005;11:483–489
  61. Schmidt M, Polasek W, Kaufeler R. Wirksamkeit und Sicherheit von Traubensilberkerze (Cimicifuga racemosa, Cimifemin®) bei Menopausebeschwerden: therapiebeobachtung unter Praxisbedingungen. J Menopause. 2005;12:27–32
  62. Vermes G, Banhidy F, Acs N. The effects of remifemin on subjective symptoms of menopause. Adv Ther. 2005;22:148–154
  63. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77:415–426
  64. Briese V, Stammwitz U, Friede M, Stefenelly U, Hnneicke-von Zepelin HH. Climateric therapy without hormones: results of a current observational cohort study. Presented at: Annual meeting of the German Menopause-Society on June 17-18, 2005, Munster, Germany.
  65. Julia MD, Garcia Y, Cano A, Arriaza E, Romeu A. A pilot study to assess changes in the quality of life in postmenopausal women after administration of Cimicifuga racemosa L., using the Cervantes scale. [abstract] Climateric. 2005;8:36
  66. Fischer J, Bartsch HH, Mumm A, Salier R, Stammwitz U, Rostock M. Prospective observational cohort study with a Cimicifuga racemosa extract (Remifemin) in breast cancer patients with climateric complaints undr therapy with tamoxifen. Presented at: Annual meeting of the German Menopause-Society on June 17-18, 2005, Munster, Germany.
  67. Henneicke-von Zepelin HH, Becher H, Schroder-Bernhardi D, Stammwith U. Pharmacoepidemiologic cohort study on the administration of Remifemin/Remifemin plus in patients with breast cancer, including hormone receptor-positive tumors. Presented at: Annual meeting of the German Menopause-Society on June 17-18, 2005, Munster, Germany.
  68. Von Schoultz B, Henneicke-von Zepelin HH, Liske E, Friede M, Hirschberg A. Clinical study on the drug safety of Remifemin with regard to breast epithelium cell proliferation and mammographic breast tissue density in postmenopausal women. Presented at: Annual meeting of the German Menopause-Society on June 17-18, 2005, Munster, Germany.
  69. Henneicke-von Zepelin HH, Meden H, Schroder-Bernhardi D, Kostev K, Becher H. Black cohosh and breast cancer recurrence-free survival. [abstract] Maturitas. 2006;54:58–59
  70. Briese V, Stammwitz U, Henneicke-von Zepelin HH. One year treatment with isopropanolic black cohosh extract (iCR). [abstract] Maturitas. 2006;54S:18S
  71. Uebelhack R, Blohmer JU, Graubaum HJ, Busch R, Gruenwald J, Wernecke KD. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol. 2006;107:247–255
  72. Bai W, Henneicke-von Zepelin HH, Zheng S, et al. Black cohosh versus tibolone in menopausal symptoms relief in Chinese women. [abstract] Maturitas. 2006;54:17
  73. Raus K, Brucker C, Gorkow C, Wuttke W. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055. Menopause. 2006;13:678–691
  74. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol. 2006;24:2836–2841
  75. Wuttke W, Gorkow C, Seidlova-Wuttke D. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause. 2006;13:185–196
  76. Guiltinan J, Newton K, Reed S, LaCroix A, Grothaus L, Ehrlich K. Results of the Herbal Alternatives for Menopause (HALT) study. Alterna Ther. 2006;12:48–49
  77. Gurley BJ, Barone GW, Williams DK, et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2006;34:69–74
  78. Gurley B, Hubbard MA, Williams DK, et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol. 2006;46:201–213
  79. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med. 2006;145:869–879
  80. Radowicki S, Skorzewska K, Rudnicka E, Szlendak-Sauer K, Wierzba W. Effectiveness and safety of the treatment of menopausal syndrome with Cimicifuga racemosa dry extract. Ginekol Pol. 2006;77:678–683
  81. Sammartino A, Tommaselli GA, Gargano V, Di Carlo C, Attianese W, Nappi C. Short-term effects of a combination of isoflavones, lignans and Cimicifuga racemosa on climacteric-related symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled trial. Gynecol Endocrinol. 2006;22:646–650
  82. Hirschberg AL, Edlund M, Svane G, Azavedo E, Skoog L, Von Schoultz B. An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. Menopause. 2007;14:89–96
  83. Zepelin HH, Meden H, Kostev K, Schroder-Bernhardi D, Stammwitz U, Becher H. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. Int J Clin Pharmacol Ther. 2007;45:143–154
  84. Verhoeven MO, Teerlink T, Kenemans P, Zuijdgeest-Van Leeuwen SD, Van Der Mooren MJ. Effects of a supplement containing isoflavones and actaea racemosa l. on asymmetric dimethylarginine, lipids, and c-reactive protein in menopausal women. Fertil Steril. 2007;87:849–857
  85. Oktem M, Eroglu D, Karahan HB, Taskintuna N, Kuscu E, Zeyneloglu HB. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Adv Ther. 2007;24:448–461
  86. Chung DJ, Kim HY, Park KH, et al. Black cohosh and St. John's wort (Gyno-Plus) for climacteric symptoms. Yonsei Med J. 2007;48:289–294
  87. Rebbeck TR, Troxel AB, Norman S, et al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer. 2007;120:1523–1528
  88. Briese V, Stammwitz U, Friede M, Henneicke-Von Zepelin HH. Black cohosh with or without St. John's Wort for symptom-specific climacteric treatment-results of a large-scale, controlled, observational study. Maturitas. 2007;57:405–414
  89. Van Der Sluijs CP, Bensoussan A, Liyanage L, Shah S. Women's health during mid-life survey: the use of complementary and alternative medicine by symptomatic women transitioning through menopause in Sydney. Menopause. 2007;14:397–403
  90. Spangler L, Newton KM, Grothaus LC, Reed SD, Ehrlich K, Lacroix AZ. The effects of black cohosh therapies on lipids, fibrinogen, glucose and insulin. Maturitas. 2007;57:195–204
  91. Bai W, Henneicke-Von Zepelin HH, Wang S, et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas. 2007;58:31–41
  92. Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med. 1996;124:726–734
  93. Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust. 2002;177:440–443
  94. Frempong W, Kiuru A, Ericsson J, Farah M. Cimicifuga racemosa L Nutt (black cohosh) and anaphylactic reactions, including face and oral oedema (The Uppsala Monitoring Centre). www.who-ucm.orgAccessed January 10, 2008
  95. Ingraffea A, Donohue K, Wilkel C, Falanga V. Cutaneous vasculitis in two patients taking an herbal supplement containing black cohosh. J Am Acad Dermatol. 2007;56:124–126
  96. Shuster J. ISMP adverse drug reactions. Hosp Pharm. 1996;31:1553–1554
  97. Lontos S, Jones RM, Angus PW, Gow PJ. Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust. 2003;179:390–391
  98. Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause. 2004;11:575–577
  99. Levitsky J, Alli TA, Wisecarver J, Sorrell MF. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci. 2005;50:538–539
  100. Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transpl. 2006;12:989–992
  101. Minciullo PL, Saija A, Patafi M, Marotta G, Ferlazzo B, Gangemi S. Muscle damage induced by black cohosh (Cimicifuga racemosa). Phytomedicine. 2006;13:115–118
  102. Meyer S, Vogt T, Obermann EC, Landthaler M, Karrer S. Cutaneous pseudolymphoma induced by Cimicifuga racemosa. Dermatology. 2007;214:94–96
  103. Dunbar K, Solga SF. Black cohosh, safety, and public awareness. Liver Int. 2007;27:1017–1018
  104. Order and Judgement 8: 05 CV 66, Grant and Beck vs Pharmavite LLC. United States District Court for the District of Nebraska. September 8, 2006.
  105. Amercian Herbal Products Association. Press release: US District Court dismisses experts and lawsuit in black cohosh complaint. September 18, 2006.
  106. Blumenthal M, Ferrier GKL, Cavaliere C. Total sales of herbal supplements in United States show steady growth. HerbalGram. 2006;71:64–66
  107. Engel W. In vivo studies on the metabolism of the monoterpene pulegone in humans using the metabolism of ingestion-correlated amounts (MICA) approach: explanation for the toxicity differences between (S)-(–)- and (R)-(+)-pulegone. J Agric Food Chem. 2003;51:6589–6597
  108. Nelson SD. Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury. Drug Metab Rev. 1995;27:147–177
  109. Chatterjee P, Franklin MR. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 2003;31:1391–1397
  110. Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia. 2001;42:1266–1272
  111. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998;158:2200–2211
  112. Thomsen M, Vitetta L, Sali A, Schmidt M. Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust. 2004;180:598–599
  113. Thomsen M, Schmidt M. Hepatotoxizität durch Cimicifuga racemosa?. Z Phytother. 2003;24:11–14
  114. Bone K. Phytotherapy review and commentary. Townsend Letter for Doctors and Patients. 2006;66–70July
  115. Freudenstein J, Dasenbrock C, Nisslein T. Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract. Cancer Res. 2002;62:3448–3452
  116. Bodinet C, Freudenstein J. Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Res Treat. 2002;76:1–10
  117. Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Evaluation of cell death caused by triterpene glycosides and phenolic substances from Cimicifuga racemosa extract in human MCF-7 breast cancer cells. Biol Pharm Bull. 2004;27:1970–1975
  118. Stromeier S, Petereit F, Nahrstedt A. Phenolic esters from the rhizomes of Cimicifuga racemosa do not cause proliferation effects in MCF-7 cells. Planta Med. 2005;71:495–500
  119. Stute P, Nisslein T, Gotte M, Kamischke A, Kiesel L, Klockenbusch W. Effects of black cohosh on estrogen biosynthesis in normal breast tissue in vitro. Maturitas. 2007;57:382–391
  120. Nisslein T, Freudenstein J. Concomitant administration of an isopropanolic extract of black cohosh and tamoxifen in the in vivo tumor model of implanted RUCA-I rat endometrial adenocarcinoma cells. Toxicol Lett. 2004;150:271–275
  121. Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis. Breast Cancer Res Treat. 2004;84:151–160
  122. Einbond LS, Shimizu M, Nuntanakorn P, et al. Actein and a fraction of black cohosh potentiate antiproliferative effects of chemotherapy agents on human breast cancer cells. Planta Med. 2006;72:1200–1206
  123. Einbond LS, Su T, Wu HA, et al. The growth inhibitory effect of actein on human breast cancer cells is associated with activation of stress response pathways. Int J Cancer. 2007;Epub ahead of print
  124. Einbond LS, Su T, Wu HA, et al. Gene expression analysis of the mechanisms whereby black cohosh inhibits human breast cancer cell growth. Anticancer Res. 2007;27:697–712
  125. Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat. 2005;90:233–239
  126. Tsukamoto S, Aburatani M, Ohta T. Isolation of CYP3A4 inhibitors from the black cohosh (Cimicifuga racemosa). Evid Based Complement Alternat Med. 2005;2:223–226

PII: S0002-9378(08)00547-4

doi: 10.1016/j.ajog.2008.05.007

American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 455-466 , November 2008

Article Tools